Sonova (OTCMKTS:SONVY – Get Free Report) and AngioDynamics (NASDAQ:ANGO – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Institutional & Insider Ownership
0.0% of Sonova shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 0.0% of Sonova shares are owned by insiders. Comparatively, 6.0% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Sonova and AngioDynamics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sonova | N/A | N/A | N/A |
| AngioDynamics | -10.01% | -4.66% | -3.08% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sonova | $4.50 billion | 3.14 | $536.96 million | N/A | N/A |
| AngioDynamics | $292.50 million | 1.75 | -$33.99 million | ($0.75) | -16.49 |
Sonova has higher revenue and earnings than AngioDynamics.
Volatility and Risk
Sonova has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Sonova and AngioDynamics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sonova | 1 | 3 | 1 | 2 | 2.57 |
| AngioDynamics | 1 | 1 | 3 | 1 | 2.67 |
AngioDynamics has a consensus price target of $18.67, suggesting a potential upside of 50.90%. Given AngioDynamics’ stronger consensus rating and higher possible upside, analysts clearly believe AngioDynamics is more favorable than Sonova.
Summary
Sonova beats AngioDynamics on 8 of the 13 factors compared between the two stocks.
About Sonova
Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.
About AngioDynamics
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Receive News & Ratings for Sonova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonova and related companies with MarketBeat.com's FREE daily email newsletter.
